Advanced search
Publication Cover
Scandinavian Journal of Urology and Nephrology Volume 26, 1992 - Issue 4
Submit an article Journal homepage
5
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Erythropoietin Treatment and Plasma Levels of Corticotropin-Releasing Hormone, Delta Sleep-Inducing Peptide and Opioid Peptides in Hemodialysis Patients

Jörgen HegbrantDepartment of Nephrology, University of Lund, Sweden
,
Hans ThysellDepartment of Nephrology, University of Lund, Sweden
&
Rolf EkmanDepartment of Psychiatry and Neurochemistry, University of Lund, Sweden
Pages 393-396 | Received 14 Jun 1991, Accepted 20 Nov 1991, Published online: 15 Feb 2010

REFERENCES

  • BiasioliS, D'AndreaG, FerianiM, ChiaramonteS, FabrisA, RoncoC, LaGreca G. Uremic encephalopathy: an updating. Clin Nephrol 1986; 25: 57–63.
  • DeferrariG, GaribottoG, RobaudoC, GhiggeriGM, TizianelloA. Brain metabolism of amino acids and ammonia in patients with chronic renal insufficiency. Kidney Int 1981; 20: 505–510.
  • EvansRW, ManninenDL, GarrisonLP Jr, HartLG, BlaggCR, GutmanRA, HullAR, LowrieEG. The quality of life of patients with end-stage renal disease. N Engl J Med 1985; 312: 553–559.
  • FraserCL, ArieffAI. Nervous system manifestations of renal failure. In: SchrierRW, GottschalkCW, editors. Diseases of the kidney. 4th ed. Boston: Little Brown and Company, 1988: 3063–3092.
  • FukunishiI, ObayashiS, ObayashiM, HosokawaK. The effect of erythropoietin on depression (I): clinical research of hemodialysis patients with depressive symptoms. XIth International Congress of Nephrology, Tokyo 1990: 203A (Abstract).
  • FukunishiI, ObayashiS, ObayashiM, HosokawaK. The effect of erythropoietin on depression (II): experimental brain research using brain microdialysis. XIth International Congress of Nephrology, Tokyo 1990: 203A (Abstract).
  • GoldbergAP, GeltmanEM, HagbergJM, GavinIII Jr, DelmezJA, CarneyRM, NaumowiczA, OldfieldMH, HarterH. Therapeutic benefits of exercise training for hemodialysis patients. Kidney Int 1983; 24 (Suppl 16): S303–S309.
  • GrimmG, StockenhuberF, SchneeweissB, MadlC, ZeitlhoferJ, SchneiderB. Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 1990; 38: 480–486.
  • GrutzmacherP, BergmannM, WeinreichT, NattermannU, ReimersE, PollockM. Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis. Contrib Nephrol 1988; 66: 104–113.
  • GutmanRA, SteadWW, RobinsonRR. Physical activity and employment status of patients on maintenance dialysis. N Engl J Med 1981; 304: 309–313.
  • HegbrantJ, ThysellH, EkmanR. Elevated plasma levels of opioid peptides and delta sleep-inducing peptide but not of corticotropin-releasing hormone in patients receiving chronic hemodialysis. Blood Purif 1991; 9: 188–194.
  • HegbrantJ, ThysellH, EkmanR. Effects of recombinant human erythropoietin on the plasma levels of vasoactive regulatory peptides in patients on maintenance hemodialysis. Int J Artif Organs 1991; 14: 411–416.
  • HirakataH, YaoH, OosatoS, OnoyamaK, FujishimaM, IchiyaY, KuwaharaY, MasudaY. Effects of erythropoietin (rHuEPO) on cerebral blood flow (CBF) and metabolism in hemodialysis (HD) patients. XIth International Congress of Nephrology, Tokyo 1990: 198A (Abstract).
  • KokotF, WiecekA, GrzeszczakW, KlepackaJ, KlinM, LaoM. Influence of erythropoietin treatment on endocrine abnormalities in haemodialyzed patients. Contrib Nephrol 1989; 76: 257–272.
  • LundinAP. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Semin Nephrol 1989; 9 (Suppl 1): 22–29.
  • MarshJT, BrownWS, WolcottD, CarrCR, HarperR, SchweitzerSV, NissensonAR. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991; 39: 155–163.
  • MayerG, ThumJ, CadaEM, StummvollHK, GrafH. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988; 34: 525–528.
  • RiedelE, HamplH, ScigallaP, NundelM, KesselM. Correction of amino acid metabolism by recombinant human erythropoietin therapy in hemodialysis patients. Kidney Int 1989; 36 (Suppl 27): S216–S221.
  • SatohK, MasudaT, IkedaY, KurokawaS, KamataK, KikawadaR, TakamotoT, MarumoF. Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients. Hypertension 1990; 15: 262–266.
  • TempleRM, LanganSJ, DearyIJ, WinneyRJ. Recombinant erythropoietin (r-EPO) improves cognitive function in chronic haemodialysis (CHD) patients. XIth International Congress of Nephrology, Tokyo 1990: 142A (Abstract).
  • VenturaMC, GonzælezR, AlarconA, MoreyA, BestardJ, ToranD, MarcoJ. Curve of perceptive intellectual deterioration in hemodialysis patients. Int J Artif Organs 1990; 13: 87–92.
  • WolcottDL, MarshJT, LaRue A, CarrC, NissensonAR. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989; XIV: 478–485.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.